Apomorphine: 4 agencies, 2011–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused apomorphine: all 11 decisive outcomes across 3 agencies were positive or positive with restrictions.
PBAC (Australia) has been easier on apomorphine than on its own caseload: it refused 0 of 8 decisive submissions here (0%), against a base rate of 24% across everything it has assessed.
The file has been open for more than a decade: 14.2 years separate the first record, 6 Jul 2011 at HAS (France), from the most recent, 18 Sep 2025 at AWMSG (Wales).
No assessment is on file from SMC (Scotland), PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 13 records date from 2023 or later.
Against its own class, apomorphine is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class G04B average 74%.
8 of these 13 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess apomorphine, on 6 Jul 2011; AWMSG (Wales) did not open a file until 18 Sep 2025 — an unusually long tail of 14.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 8 years in total.
2 of the 4 agencies here assessed apomorphine more than once, PBAC (Australia) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed apomorphine.
The full ledger for apomorphine reads 11 recommended, 1 not assessed and 1 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 18 Sep 2025 | Intermittent treatment of “OFF” episodes in adult patients with Parkinson's disease (PD) which are not sufficiently cont… | outside AWMSG criteria | source |
| PBAC (Australia) | 2025 | Parkinson disease | Recommended | source |
| CIPM (Spain) | 24 Apr 2024 | Indicación terapéutica autorizada: Tratamiento intermitente de los episodios “OFF” en pacientes adultos con enfermedad d… | financed by the SNS · art. 92 a, b | source |
| HAS (France) | 11 Jan 2017 | Listing renewal (Transparency Committee) | SMR substantial | source |
| HAS (France) | 6 Jul 2011 | Listing (Transparency Committee) | ASMR V | source |
8 further decisions for apomorphine, across 2 agencies, are not shown here.
Related molecules
- sildenafil — same ATC class G04B — Urologicals
- tadalafil — same ATC class G04B — Urologicals
- mirabegron — same ATC class G04B — Urologicals
- solifenacin — same ATC class G04B — Urologicals
- vibegron — same ATC class G04B — Urologicals
- oxybutynin — same ATC class G04B — Urologicals
Coverage: 13 decisions for apomorphine from 4 agencies, 2011 to 2025. Data to 7 Sep 2026. ATC class G04B — Urologicals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.